APELLIS PHARMACTDL Financials
| 1JK Stock | EUR 28.70 0.21 0.74% |
APELLIS |
Understanding current and past APELLIS PHARMACTDL Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of APELLIS PHARMACTDL's financial statements are interrelated, with each one affecting the others. For example, an increase in APELLIS PHARMACTDL's assets may result in an increase in income on the income statement.
APELLIS PHARMACTDL Stock Summary
APELLIS PHARMACTDL competes with Novo Nordisk, CSL, CSL, Mercedes Benz, and Vertex Pharmaceuticals. Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. APELLIS PHARMACT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 445 people.| Instrument | Germany Stock View All |
| Exchange | Frankfurt Exchange |
| ISIN | US03753U1060 |
| Business Address | 100 Fifth Avenue |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.apellis.com |
| Phone | 617 977 5700 |
| Currency | EUR - Euro |
You should never invest in APELLIS PHARMACTDL without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of APELLIS Stock, because this is throwing your money away. Analyzing the key information contained in APELLIS PHARMACTDL's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
APELLIS PHARMACTDL Key Financial Ratios
There are many critical financial ratios that APELLIS PHARMACTDL's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that APELLIS PHARMACTDL 0001 reports annually and quarterly.| Return On Equity | -5.07 | |||
| Return On Asset | -0.46 | |||
| Target Price | 67.81 | |||
| Number Of Employees | 767 | |||
| Beta | 1.23 |
APELLIS Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining APELLIS PHARMACTDL's current stock value. Our valuation model uses many indicators to compare APELLIS PHARMACTDL value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across APELLIS PHARMACTDL competition to find correlations between indicators driving APELLIS PHARMACTDL's intrinsic value. More Info.APELLIS PHARMACTDL 0001 is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the APELLIS PHARMACTDL's earnings, one of the primary drivers of an investment's value.APELLIS PHARMACTDL 0001 Systematic Risk
APELLIS PHARMACTDL's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. APELLIS PHARMACTDL volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on APELLIS PHARMACTDL 0001 correlated with the market. If Beta is less than 0 APELLIS PHARMACTDL generally moves in the opposite direction as compared to the market. If APELLIS PHARMACTDL Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one APELLIS PHARMACTDL 0001 is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of APELLIS PHARMACTDL is generally in the same direction as the market. If Beta > 1 APELLIS PHARMACTDL moves generally in the same direction as, but more than the movement of the benchmark.
APELLIS PHARMACTDL January 27, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of APELLIS PHARMACTDL help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of APELLIS PHARMACTDL 0001. We use our internally-developed statistical techniques to arrive at the intrinsic value of APELLIS PHARMACTDL 0001 based on widely used predictive technical indicators. In general, we focus on analyzing APELLIS Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build APELLIS PHARMACTDL's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.47 | |||
| Information Ratio | 0.0567 | |||
| Maximum Drawdown | 24.4 | |||
| Value At Risk | (4.88) | |||
| Potential Upside | 7.31 |
Complementary Tools for APELLIS Stock analysis
When running APELLIS PHARMACTDL's price analysis, check to measure APELLIS PHARMACTDL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy APELLIS PHARMACTDL is operating at the current time. Most of APELLIS PHARMACTDL's value examination focuses on studying past and present price action to predict the probability of APELLIS PHARMACTDL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move APELLIS PHARMACTDL's price. Additionally, you may evaluate how the addition of APELLIS PHARMACTDL to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |